Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine/fluoxetine capsule in bipolar I depression
CTR20191330Phase 3Completed
- Sponsor
- Jiangsu Changtai Pharmaceutical
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine + fluoxetine in bipolar I disorder, major depressive disorder (MDD), sponsored by Jiangsu Changtai Pharmaceutical. Started Jul 2019; status: completed.
02
Drugs
olanzapine + fluoxetine
03
Conditions
bipolar I disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20191330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191330.